Similarly, HV-3 treatment suppressed the VCP translocation to mitochondria that occurred in striatum of HD R6/2 mice expressing an N-terminal mtHtt fragment (Fig. 3i, treatment timeline in Supplementary Fig. 5a). Here, VCP is linked to Huntington disease.